Go Pro
NASDAQ:WHWK

Whitehawk Therapeutics Q1 2026 Earnings Report

Whitehawk Therapeutics logo
$3.82 -0.22 (-5.45%)
Closing price 04:00 PM Eastern
Extended Trading
$3.88 +0.06 (+1.44%)
As of 05:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Whitehawk Therapeutics EPS Results

Actual EPS
-$0.32
Consensus EPS
-$0.36
Beat/Miss
Beat by +$0.04
One Year Ago EPS
N/A

Whitehawk Therapeutics Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Whitehawk Therapeutics Announcement Details

Quarter
Q1 2026
Time
Before Market Opens
Conference Call Date
N/A
Conference Call Time
N/A

Conference Call Resources

Whitehawk Therapeutics Earnings Headlines

ALERT: Drop these 5 stocks before the market opens tomorrow!
The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings research points to the first half of 2026 as a particularly rough stretch for certain holdings. Some of America's most popular stocks could take serious damage as a radical market shift plays out. Analysts at Weiss Ratings have identified five names you may want to remove from your portfolio before this unfolds. If any of these are in your portfolio, now is the time to review your positions.tc pixel
Whitehawk Therapeutics Adds Oncology Leader to Board
See More Whitehawk Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Whitehawk Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Whitehawk Therapeutics and other key companies, straight to your email.

About Whitehawk Therapeutics

Whitehawk Therapeutics (NASDAQ:WHWK) (NASDAQ: WHWK) is a clinical-stage biopharmaceutical company focused on developing new medicines for cancer. Its research is centered on antibody-drug conjugates, which are designed to use targeted antibodies to deliver cancer-killing agents directly to tumor cells.

The company is advancing a pipeline of oncology therapies intended to address cancers with significant unmet medical needs. Its activities include drug discovery, preclinical research and clinical development, with programs designed to evaluate the safety and potential effectiveness of its targeted therapeutic candidates.

Whitehawk Therapeutics is an early-stage biotechnology company, and its pipeline remains subject to the clinical, regulatory and commercialization risks associated with developing experimental medicines. The company’s publicly available profile provides limited additional information about its leadership, operating geographies and specific product candidates.

View Whitehawk Therapeutics Profile